Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 6, 2017
Financial Milestone Achieved in Catalyst’s Subcutaneous Factor IX Program
SOUTH SAN FRANCISCO, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
July 6, 2017
Prometic announces closing of equity offerings for aggregate gross proceeds of $61.7 million
LAVAL, QC , July 6, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") announced today that it has closed the previously ...
July 5, 2017
Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration
Onxeo S.A. (ONXEO.PA) (NASDAQ OMX:ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan ...
July 5, 2017
BioLife Solutions Modifies Existing Credit Facility
BOTHELL, Wash., July 5, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage ...
July 5, 2017
CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank
MONMOUTH JUNCTION, N.J., July 5, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy specializing in blood purification, announced that on June 30, 2017 it received an additional ...
July 5, 2017
Soleno Therapeutics Announces Successful Completion of FDA Meeting for DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif., July 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
July 5, 2017
Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
BRISBANE, Calif.--(BUSINESS WIRE) -- Aimmune Therapeutics, Inc. (AIMT), today announced the enrollment of its first patient in the European Phase 3 ARTEMIS (ARC010) clinical trial of ...
July 5, 2017
IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of Ceplene® in Combination with Low-Dose IL-2 in Patients With Acute Myeloid Leukemia, Recently Published in Leukemia, a Leading Hematology Journal
NEW YORK, July 5, 2017 /PRNewswire/ -- Cytovia, the oncology subsidiary of Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company (IMNP) ("Immune" or the "Company") announced ...
July 5, 2017
Oramed Announces Dual-Listing on Tel Aviv Stock Exchange
JERUSALEM, July 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced ...
July 5, 2017
Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., July 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced public ...
July 5, 2017
Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease
DUBLIN, Ireland, July 05, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of ...
June 5, 2017
New Microbiology Data Reinforce Activity of Paratek’s Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections
NEW ORLEANS, June 03, 2017 (GLOBE NEWSWIRE) -- New data presented today at ASM Microbe 2017 showed that Paratek Pharmaceuticals, Inc.’s (PRTK) Phase 3 antibiotic ...
June 5, 2017
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
ROCKVILLE, Md., June 04, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
June 5, 2017
Kamada Announces Appointment of Michal Stein, M.D., as Vice President and Medical Director
REHOVOT, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the appointment of ...
June 5, 2017
Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials of Chk1 Inhibitor SRA737
VANCOUVER , June 5, 2017 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...
June 5, 2017
MediWound to Present at the Jefferies Global Healthcare Conference
YAVNE, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn ...
June 5, 2017
New Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
TEL AVIV, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), today announced the presentation of new data demonstrating that treatment with VB-111 (ofranergene ...
June 5, 2017
Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting
NEW ORLEANS, June 05, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today ...
June 5, 2017
Aurinia Presents Additional Data from Phase Iib Aura-Lv Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (AUPH)(AUP.TO) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, presented additional data ...
June 5, 2017
Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting
NEWTOWN, Pa., June 05, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small ...
Page 107 of 117